BofA lowered the firm’s price target on Crispr Therapeutics to $100 from $110 and keeps a Buy rating on the shares. Crispr had “a strong 2023,” with shares outperforming the broader biotech market, but the firm expects “commercial hurdles” for Casgevy to weigh on the stock looking to 2024, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics positioned for European approval, says Piper Sandler
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Crispr Therapeutics price target raised by $4 at Morgan Stanley, here’s why
- CRISPR Therapeutics (NASDAQ:CRSP) Tanks after Analyst Downgrade